Skip to main content

Advertisement

Table 1 Patient characteristics

From: High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis

  EGPA patients who received IVIG during initial treatment (n = 10) EGPA patients who received IVIG on relapse after remission (n = 7) P
Age (y), mean ± 1 SD 59.1 ± 15.2 47.9 ± 18.3 NS
Sex (M/F) 4/6 3/4 NS*
Age at onset EGPA (y), mean ± 1 SD 57.0 ± 42.6 42.6 ± 20.0 NS
At onset of EGPA    
  WBC (/μL), mean ± 1 SD 13,573 ± 4,647 16,930 ± 6,728 NS
  Blood eosinophils (/μL), mean ± 1 SD 6,681 ± 3,698 7,363 ± 6,686 NS
  MPO-ANCA (%) at onset 40 28.6 NS*
  PR3-ANCA (%) at onset 0 0 NS*
At initial IVIG treatment    
  WBC (/mL), mean ± 1 SD 9,912 ± 3,339 8,093 ± 2,752 NS
  Blood eosinophils (/μL), mean ± 1 SD 79.6 ± 69.2 252.3 ± 182.7 <0.05
  FOXP3+CD4+ T cells (%), mean ± 1 SD 2.4 ± 1.6 1.3 ± 1.1 <0.05
Time from onset of EGPA to initial IVIG treatment (mo), median (range) 3.0 (1–3) 65.0 (10–122) <0.01††
Number of IVIG treatments needed to achieve first remission (one/two or more) 3/7 5/2 NS*
Initial treatments at onset    
  Prednisolone (mg), mean ± 1 SD 50.5 ± 10.5 48.6 ± 10.7 NS
  Patients taking an immunosuppressant (%) 90 42.9 < 0.05*
CYC/AZA/CSA 8/0/1 1/1/1 NS*
Other treatments at initial IVIG    
  Prednisolone (mg), mean ± 1 SD 39.5 ± 11.2 12.9 ± 5.5 0.01
  Patients taking an immunosuppressant (%) 90 71.4 NS*
CYC/AZA/CSA 8/0/1 1/3/1 0.05*
  1. AZA, azathioprine; CYC, cyclophosphamide; CSA, cyclosporin; EGPA, eosinophilic granulomatosis with polyangiitis; IVIG, intravenous immunoglobulin; MPO-ANCA, myeloperoxidase-specific antineutrophil cytoplasmic antibodies; NS, not significant; PR3, protein 3; WBC, white blood cells.
  2. All values are expressed as means ± 1 SD.
  3. Values of P < 0.05 were considered statistically significant.
  4. Two-way ANOVA with repeated measures between groups.
  5. ††Statistical comparisons made by using Mann–Whitney U-tests between groups.
  6. *Chi-squared testing revealed no significant differences in frequencies between the two groups.